hanpoong pharm
  • 서브비주얼 1
  • 서브비주얼 2
  • 서브비주얼 3
customer service center
oem & odm

Ⅰ. Medicine for Alzheimer’s disease - LMK02 (Clinical Trials Management Division -483)

- Phase 2 clinical trial conducted to examine the safety and determine the appropriate dosage of LMK02 for treating mild to moderate Alzheimer’s disease

- Multi-institutional, randomized, double-blind, multi-dose, placebo-controlled trial



Ⅱ. Combination therapy with mesalazine to treat ulcerative colitis - HP1104 (Clinical Trials Management Division -605)

- Phase 2 clinical trial conducted to determined the dosage and confirm the safety of oral intake of Raphanus sativus Linne. tablets (radish tablets) as a combination therapy with mesalazine to treat patients with mild/moderate ulcerative colitis

A 8-week randomized, double-blind, comparative medicine and placebo-controlled, parallel designed and multi-institutional trial



Ⅲ. Medicine for Alzheimer’s disease - KSOP1009 (Clinical Trials Management Division - 2089)

- Phase 2 clinical trial conducted to examine the safety and determine the appropriate dosage of KSOP1009 for treating mild to moderate Alzheimer’s disease

- Multi-institutional, randomized, double-blind, placebo-controlled  and parallel designed trial

    hanpoong pharm

    Company: Hanpoong Pharm. Co Ltd,. / CEO: JO, INSIK / Phone: 82-2-6909-5100  FAX : 82-2-583-8584

    Address: 100 Hyoryeong-roSeocho-gu, Seoul (Bangbae-dong)

    Copyrightⓒ HANPOONG PHARM & FOODS Co, Ltd,.  All rights reserved.